Paradigm Funds Final Push Towards Phase 3 Osteoarthritis Data

Final Tranche 4 Drawdown Adds Working Capital

Paradigm Biopharmaceuticals Ltd. (ASX:PAR) has drawn the remaining US$2 million of Tranche 4 under its convertible note facility with Obsidian Global Partners, adding approximately A$2.8 million to the company’s working capital position. The drawdown takes the total facility to its latest stage, with about US$5 million, or approximately A$6.9 million, still available.

The funding is aimed at keeping Paradigm’s global Phase 3 PARA_OA_012 trial moving through its next operational phase. The company says the money will support ongoing clinical operations, database management and regulatory activities as it progresses towards its planned interim analysis and subsequent top-line primary endpoint readout.

538 Participants Carry Trial Into Data Collection

Recruitment is complete, with 538 participants enrolled across clinical sites in the United States, Australia, Hong Kong and Moldova. That is above the original target of 466 participants, although the announcement provides no new efficacy or safety results.

With enrolment finished, the focus shifts to patient treatment, follow-up assessments and data collection for injectable pentosan polysulfate sodium, or iPPS, in knee osteoarthritis. Paradigm describes the trial as fully funded through the planned interim analysis and top-line primary endpoint readout, but the timing and outcome of those milestones remain subject to the clinical programme’s stated risks and uncertainties.

Remaining Facility Capacity Keeps Financing Question Open

The additional drawdown improves near-term funding flexibility, but it also leaves a financing question beyond the planned clinical readouts. Paradigm has not disclosed in this announcement whether the remaining US$5 million will be drawn, nor does the release provide the conversion terms or potential dilution associated with the facility.

For now, the next material test is operational rather than financial: whether the completed trial can produce the interim and top-line data needed to advance iPPS towards its potential commercial and regulatory pathway. Until those results arrive, the latest capital update strengthens execution capacity without changing the underlying clinical uncertainty.